Robert Nelsen Overview

  • Investor Type
  • Angel
  • Investments
  • 8
  • Portfolio
  • 3
  • Exits
  • 2
Exits

Robert Nelsen General Information

Description

Mr. Robert Nelsen is a Co-Founder and serves as a Managing Director at ARCH Venture Partners. He was a Board Member of Arivale. He serves as Chairman at Resilience. He is a Co-Founder and Board Member of Vir Biotechnology and Brii Biosciences. He serves as Board Member at Nutcracker, Therapeutics, insitro, Encoded Therapeutics, Beam Therapeutics, Grail (Biotechnology) and Lyell. He is a Board Member of Sana Biotechnology. He is also a Board Member of Agios Pharmaceuticals since December 2007. Additionally, he also served as an Advisor at Mighty AI. He is a Co-Founder of ARCH Venture Partners, a venture capital firm and has served in various capacities for ARCH and affiliated entities since 1986. He is currently a Managing Director of ARCH Venture Corporation. He has played a significant role in the early sourcing, financing and development of more than 30 companies. He served as Board Member at Ensemble Therapeutics. He is a Director of Sapphire Energy, Inc., Ensemble Therapeutics Corporation, Juno Therapeutics, Inc., Syros Pharmaceuticals Inc., Denali Therapeutics and Faraday Pharmaceuticals, Inc. among other companies. He previously served on the boards of Bellerophon Therapeutics, Inc., Fate Therapeutics, Inc., Elixir Pharmaceuticals, Inc., Ikaria Inc., Kythera Biopharmaceuticals, Inc., NeurogesX, Inc., Sage Therapeutics, Inc. and entities affiliated with deCode Genetics, Inc., among others. He was previously a Trustee of the Fred Hutchinson Cancer Research Institute, the Institute for Systems Biology and a director of the National Venture Capital Association. He received a B.S. with majors in biology and economics from the University of Puget Sound and an M.B.A. from the University of Chicago. He serves as Advisor at CityBldr

Contact Information

Primary Investor Type
Angel (individual)

Robert Nelsen Investments (8)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
Gali Health 17-May-2019 Seed Round 00.00 Other Healthcare Technology Systems Startup 000000 000000
00000 02-Aug-2018 00000 00000 000.00 Recreational Goods Generating Revenue 000000 000000
0000000 000000 000 18-Jan-2018 00000 00000 0000 Consulting Services (B2B) Startup 000000 000000
0000000 000000 06-Dec-2016 00000 00000 0000 Pharmaceuticals Generating Revenue 000000 000000
00000 24-May-2016 00000 00000 0000 Recreational Goods Generating Revenue 000000 000000
00000 20-Jan-2016 0000 00000 00.00 Recreational Goods Generating Revenue 000000 000000
Pioneer Square Labs (PSL Studio) 01-Oct-2015 Early Stage VC 000.00 Consulting Services (B2B) Startup 000000 000000
Mighty AI 08-Dec-2014 Seed Round 00.000 Road Generating Revenue 000000 000000
To view Robert Nelsen’s complete investments history, request access »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Robert Nelsen Exits (2)

Company Name Exit Date Exit Type Exit Size
VICIS 31-Dec-2019 Bankruptcy: Admin/Reorg
000000 00 25-Jun-2019 000000000000000000
To view Robert Nelsen’s complete exits history, request access »

Robert Nelsen Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Robert Nelsen Team (1)

Name Title Deals Funds Boards Office
Robert Nelsen Angel Investor 00 0 00 Seattle, WA
To view Robert Nelsen’s complete team members history, request access »

Robert Nelsen Co-Investors (39)

Name With Exits Lead Partner Series Industry
Sudhir Singh 2 0 0 Series chart Industry bar
Trilogy Equity Partners 0 0 0 Series chart Industry bar
Greycroft 0 0 Series chart Industry bar
Madrona Venture Group 0 0 Series chart Industry bar
Maveron 0 0 Series chart Industry bar
You’re viewing 5 of 39 co-investors. Get the full list »